Cabot Corp

CBT is in a robust Stage 2 uptrend with clear sequential higher highs and higher lows underpinned by rising EMAs, supportive volume, and relative strength leadership. The medium-term bias remains bullish, and short-term conditions are favorable with price tightly tracking rising 9/21 EMAs without overextended stress. A buy now is warranted on continuation participation at the breakout area, with execution aligned to the advancing trend and awaiting acceptance beyond recent highs.

• ↑High earnings yield and 1.11x book-to-price support valuation upside.
• ↑Q2 adjusted EPS $1.90, up 7% YoY, shows operational resilience.
• ↓Adjusted Q2 EPS $1.61, down 15% YoY, reflecting segment weakness.